+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
A

Actively Recruiting

Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
60 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of the drug IMVT-1402 in adults with Graves disease who remain hyperthyroid despite treatment with antithyroid drugs. This randomized, double-blind, placebo-controlled Phase 2b trial aims to compare IMVT-1402 with a placebo by measuring thyroid hormone levels and antithyroid drug doses at 26 weeks. Participants receive IMVT-1402 through weekly injections under the skin at a dose of 600 mg. Different groups receive the drug for either 52 weeks continuously, 26 weeks followed by placebo for 26 weeks, or placebo only for 52 weeks. The study involves a parallel design where participants are assigned to one of these groups randomly. During the study, participants will have their thyroid hormone levels, including T3, FT3, FT4, and TSH, monitored regularly along with their antithyroid drug use. Assessments occur at various time points up to 104 weeks to evaluate thyroid function and antibody levels. Safety and tolerability will also be observed throughout the trial to understand the drugs effects over time.

Age: 18Years - 75YearsAll GendersPhase 2
134 locations
A

Actively Recruiting

Researchers are studying VX-993 to evaluate its effectiveness, safety, and tolerability in adults with pain caused by Diabetic Peripheral Neuropathy DPN, a condition linked to diabetes that affects nerve function in the lower limbs. This Phase 2 trial compares VX-993 with Pregabalin, an existing medication used to manage this type of pain, to better understand how these treatments work for participants with DPN. Participants are randomly assigned to receive either varying doses of oral VX-993 tablets or Pregabalin capsules. The study is double-blind and includes matched placebos for both treatments to maintain unbiased results. The trial lasts up to 16 weeks, with primary evaluations focused at 12 weeks to measure changes in pain intensity using a numeric scale. During the trial, participants will undergo regular assessments of their daily pain levels and monitoring for any adverse effects. Researchers will track the percentage of pain reduction and evaluate safety through reports of side effects. The study spans from initial screening through treatment and follow-up, with ongoing safety assessments to support participant well-being throughout the process.

Age: 18Years - 80YearsAll GendersPhase 2
47 locations
E

Actively Recruiting

Researchers are evaluating a new combination of three drugsIsatuximab, Iberdomide, and Dexamethasonein adults with intermediate or high risk smouldering myeloma. This early form of myeloma can progress slowly to active multiple myeloma, and the study aims to see if this drug combination can prevent or delay disease progression while being tolerated and accepted by patients. Participants will receive treatment over two years, divided into 26 cycles of 28 days each, organized into three stages induction cycles 1-4, consolidation cycles 5-13, and maintenance cycles 14-26. Isatuximab is given subcutaneously via a medical device with varying frequency across stages, while Iberdomide and Dexamethasone are administered orally with specific dosing schedules throughout the treatment period. During the study, participants will be regularly monitored for treatment delivery and effectiveness, including response rates and safety. Researchers will assess progression-free survival, disease biomarkers, adverse events, and patient-reported outcomes through questionnaires and laboratory tests. Follow-up extends up to 5.5 years for long-term outcomes, with safety monitoring continuing for six months after treatment ends.

Age: 18Years +All GendersPhase 2
14 locations
C

Actively Recruiting

Researchers are conducting a phase III, randomized, open-label, international trial to compare ruxolitinib with the best available therapy, which includes either hydroxycarbamide or interferon alpha, as first-line treatment for patients with high-risk polycythemia vera. This trial aims to assess the effectiveness and safety of these treatments in managing the disease and preventing major complications such as thrombosis and transformation to other blood disorders. Participants will be randomly assigned to receive either ruxolitinib at a dose of 10 mg twice daily or best available therapy consisting of hydroxycarbamide or any formulation of interferon alpha chosen by the investigator before randomization. The study prohibits crossover between treatment arms during the trial period. Treatment and monitoring will continue for approximately 3 years, with assessments of blood markers, symptom burden, quality of life, and adverse events. During the trial, participants will have regular visits for monitoring their health, including blood tests for JAK2 V617F allele burden, quality of life questionnaires at several time points, and evaluation of clinical events such as thrombosis, haemorrhage, and disease progression. The primary outcome measured is event-free survival, defined by the time until major complications or death within the trial duration. Safety, symptom changes, and other secondary outcomes will be assessed continuously throughout the study, which is planned to complete by 2030.

Age: 18Years +All GendersPhase 3
55 locations
P

Actively Recruiting

Researchers are evaluating the impact of implantable cardioverter-defibrillators ICDs on patients who have survived a myocardial infarction heart attack and have a severely reduced left ventricular ejection fraction LVEF of 35% or less. This group is at increased risk of sudden cardiac death caused by dangerous heart rhythms. Past landmark trials showed ICDs improved survival, but advances in medical therapy have changed patient outcomes, prompting the need to reassess the benefits and risks of ICDs alongside current optimal treatments. In this randomized trial, participants receive optimal medical therapy OMT based on European Society of Cardiology guidelines for managing heart failure and chronic coronary syndromes. One group will also receive an ICD device, while the other group will not. The study compares outcomes between these two groups to determine if OMT without ICD is not worse than OMT with ICD in preventing death. The trial includes patients with symptomatic heart failure and reduced LVEF after a myocardial infarction. Participants will be followed over time with regular evaluations to monitor health and outcomes. Researchers will measure the time from randomization to death from any cause as the primary outcome, with additional assessments including cardiovascular death, sudden cardiac death, hospital readmissions, length of hospital stays, and quality of life over a year. The study is event-driven and expects to observe outcomes about 15 months after the last participant is enrolled. Safety and effectiveness of treatments will be carefully monitored throughout.

Age: 18Years +All GendersPhase Not Applicable
86 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations

1-10 of 14

1